CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni PT, Bassani F, Caruso P, Bergamaschi M, Pisano AR, Puviani V, Stellari FF, Cenacchi V, Volta R, Bertacche V, Mileo V, Bagnacani V, Moretti E, Puccini P, Catinella S, Facchinetti F, Sala A, Civelli M.
Villetti G, et al. Among authors: bergamaschi m.
J Pharmacol Exp Ther. 2015 Mar;352(3):568-78. doi: 10.1124/jpet.114.220558. Epub 2015 Jan 9.
J Pharmacol Exp Ther. 2015.
PMID: 25576073